Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.

Zander SA, Sol W, Greenberger L, Zhang Y, van Tellingen O, Jonkers J, Borst P, Rottenberg S.

PLoS One. 2012;7(9):e45248. doi: 10.1371/journal.pone.0045248. Epub 2012 Sep 17.

2.

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.

Zander SA, Kersbergen A, van der Burg E, de Water N, van Tellingen O, Gunnarsdottir S, Jaspers JE, Pajic M, Nygren AO, Jonkers J, Borst P, Rottenberg S.

Cancer Res. 2010 Feb 15;70(4):1700-10. doi: 10.1158/0008-5472.CAN-09-3367. Epub 2010 Feb 9.

3.

Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrol.

Zander SA, Kersbergen A, Sol W, Gonggrijp M, van de Wetering K, Jonkers J, Borst P, Rottenberg S.

Cancer Prev Res (Phila). 2012 Aug;5(8):1053-60. doi: 10.1158/1940-6207.CAPR-12-0050. Epub 2012 Jul 5.

4.

Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.

Pastorino F, Loi M, Sapra P, Becherini P, Cilli M, Emionite L, Ribatti D, Greenberger LM, Horak ID, Ponzoni M.

Clin Cancer Res. 2010 Oct 1;16(19):4809-21. doi: 10.1158/1078-0432.CCR-10-1354. Epub 2010 Aug 11.

5.

ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.

Candeil L, Gourdier I, Peyron D, Vezzio N, Copois V, Bibeau F, Orsetti B, Scheffer GL, Ychou M, Khan QA, Pommier Y, Pau B, Martineau P, Del Rio M.

Int J Cancer. 2004 May 10;109(6):848-54.

6.

FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.

Westover D, Ling X, Lam H, Welch J, Jin C, Gongora C, Del Rio M, Wani M, Li F.

Mol Cancer. 2015 Apr 28;14:92. doi: 10.1186/s12943-015-0362-9.

7.

Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.

Gounder MK, Nazar AS, Saleem A, Pungaliya P, Kulkarni D, Versace R, Rubin EH.

Invest New Drugs. 2008 Jun;26(3):205-13. Epub 2007 Oct 18.

PMID:
17943230
8.

BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.

Nagashima S, Soda H, Oka M, Kitazaki T, Shiozawa K, Nakamura Y, Takemura M, Yabuuchi H, Fukuda M, Tsukamoto K, Kohno S.

Cancer Chemother Pharmacol. 2006 Nov;58(5):594-600. Epub 2006 Mar 7.

PMID:
16520985
9.

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.

Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P.

Cancer Res. 2004 Apr 1;64(7):2333-7.

10.

ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties.

Wang F, Liang YJ, Wu XP, Su XD, Fu LW.

Chin J Cancer. 2012 Mar;31(3):150-8. doi: 10.5732/cjc.011.10310. Epub 2012 Feb 24.

11.

Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.

Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S.

Int J Cancer. 2004 Jan 1;108(1):146-51.

12.

Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.

Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JH, Beijnen JH, van Tellingen O.

Clin Cancer Res. 2013 Apr 15;19(8):2084-95. doi: 10.1158/1078-0432.CCR-12-3105. Epub 2013 Mar 5.

13.

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.

Rottenberg S, Nygren AO, Pajic M, van Leeuwen FW, van der Heijden I, van de Wetering K, Liu X, de Visser KE, Gilhuijs KG, van Tellingen O, Schouten JP, Jonkers J, Borst P.

Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12117-22. Epub 2007 Jul 11.

14.

The impact of ABCG2 on bovine mammary epithelial cell proliferation.

Wei J, Geale PF, Sheehy PA, Williamson P.

Anim Biotechnol. 2012;23(3):221-4. doi: 10.1080/10495398.2012.696567.

PMID:
22870877
15.

Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.

Bakhsheshian J, Wei BR, Chang KE, Shukla S, Ambudkar SV, Simpson RM, Gottesman MM, Hall MD.

Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20801-6. doi: 10.1073/pnas.1312159110. Epub 2013 Dec 2.

16.

Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.

Poller B, Wagenaar E, Tang SC, Schinkel AH.

Mol Pharm. 2011 Apr 4;8(2):571-82. doi: 10.1021/mp1003898. Epub 2011 Mar 4.

PMID:
21309545
17.

ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy.

Morfouace M, Cheepala S, Jackson S, Fukuda Y, Patel YT, Fatima S, Kawauchi D, Shelat AA, Stewart CF, Sorrentino BP, Schuetz JD, Roussel MF.

Cancer Res. 2015 Sep 15;75(18):3879-89. doi: 10.1158/0008-5472.CAN-15-0030. Epub 2015 Jul 21.

18.

The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).

González-Sarrías A, Miguel V, Merino G, Lucas R, Morales JC, Tomás-Barberán F, Alvarez AI, Espín JC.

J Agric Food Chem. 2013 May 8;61(18):4352-9. doi: 10.1021/jf4007505. Epub 2013 Apr 24.

PMID:
23586460
19.

Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S.

Cancer Res. 2005 Feb 15;65(4):1541-6.

20.

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. doi: 10.1073/pnas.0806092105. Epub 2008 Oct 29.

Supplemental Content

Support Center